Rosuvastatin

Drug Profile

Rosuvastatin

Alternative Names: Crestor; CRESTOR OD; Rosuvas; Rosuvastatin calcium; S 4522; ZD 4522

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Shionogi
  • Developer AstraZeneca; Shionogi
  • Class Antihyperlipidaemics; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atherosclerosis; Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia; Hypertriglyceridaemia
  • Discontinued Heart failure

Most Recent Events

  • 03 Mar 2017 Yuhan Corporation plans a phase III trial for Hypertension and Hyperlipidaemia (Combination therapy) (NCT03067688)
  • 30 Nov 2016 AstraZeneca completes the extension study of the phase III HYDRA trial for Hypercholesterolaemia (In adolescents, In children) in Belgium, Canada, Denmark, Israel, Malaysia and Taiwan (NCT02434497)
  • 27 Aug 2016 Pooled efficacy and adverse events data from the phase III HYDRA and CHARON trials in Hypercholesterolaemia (In children, In adolescents) released by AstraZeneca
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top